AZN : Imfinzi Plus Chemotherapy Triples Patient Survival At 3-yrs In ES-Small Cell Lung Cancer
18/9 19:47
(RTTNews) - AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi or durvalumab in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival benefit at three years for adults with extensive-stag...